The role of hypersympathycotony in development of arterial hypertensionin patients with metabolic syndrome: potential of pathogenetically sound therapy
- Authors: Ametov AS1, Demidova TY.1, Smagina LV1
-
Affiliations:
- Issue: Vol 79, No 12 (2004)
- Pages: 27-32
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/29931
- ID: 29931
Cite item
Full Text
Abstract
Aim. To assess hypotensive efficacy and metabolic neutrality of moxonidine (physiotenz) - a selective
agonist of imidasoline receptors - in patients with mild and moderate arterial hypertension (AH) associated
with diabetes mellitus (DM) type 2.
Material and methods. Follow-up and treatment were conducted in 30 hypertensive diabetics (mean
age 52.43 ± 4.65 years). Mean duration of DM and AH was 4.77 ± 2.69 and 6.93 ± 2.98 years, respectively.
The study was made of lipid exchange, glycemia, levels of glycosylated hemoglobin (GH),
fasting and postprandial immunoreactive insulin. Hypotensive efficacy was examined by 24-h monitoring
of arterial pressure after 16 weeks of therapy.
Results. Mean 24-h systolic arterial pressure fell by 8.02%, diastolic arterial pressure - by 6.47%.
The drug had a good effect on a 24-h profile of arterial pressure: a significant decrease of day and
night pressure load index, lowering of initially high 24-h variability of systolic and diastolic arterial
pressure, normalization of two-phase profile of arterial pressure. Carbohydrate metabolism improved
also: GH, glycemia, immunoreactive insulin decreased. There was a significant trend to a change in
qualitative composition of blood lipids - a decrease in lipoproteins atherogenic fractions and a rise in
HDLP.
Conclusion. Physiotens is a highly effective hypotensive drug for use in mild and moderate AH in DM
of type 2.
agonist of imidasoline receptors - in patients with mild and moderate arterial hypertension (AH) associated
with diabetes mellitus (DM) type 2.
Material and methods. Follow-up and treatment were conducted in 30 hypertensive diabetics (mean
age 52.43 ± 4.65 years). Mean duration of DM and AH was 4.77 ± 2.69 and 6.93 ± 2.98 years, respectively.
The study was made of lipid exchange, glycemia, levels of glycosylated hemoglobin (GH),
fasting and postprandial immunoreactive insulin. Hypotensive efficacy was examined by 24-h monitoring
of arterial pressure after 16 weeks of therapy.
Results. Mean 24-h systolic arterial pressure fell by 8.02%, diastolic arterial pressure - by 6.47%.
The drug had a good effect on a 24-h profile of arterial pressure: a significant decrease of day and
night pressure load index, lowering of initially high 24-h variability of systolic and diastolic arterial
pressure, normalization of two-phase profile of arterial pressure. Carbohydrate metabolism improved
also: GH, glycemia, immunoreactive insulin decreased. There was a significant trend to a change in
qualitative composition of blood lipids - a decrease in lipoproteins atherogenic fractions and a rise in
HDLP.
Conclusion. Physiotens is a highly effective hypotensive drug for use in mild and moderate AH in DM
of type 2.
References
- Ford E. S., Cooper R. S. Risk factors for hypertension a national cohort study. Hypertension 1991; 18(5): 598-606.
- Hall J. E., Brands M. W., Henegar J. R. Mechanisms of hypertension and kidney disease in obesity. Ann. N. Y. Acad. Sci. 1999; 892: 91-107.
- Guidelines Subcommitte. 1999. World Health Organozation - International Society of Hypertension guidelines for the management of hypertension. J. Hypertens. 1999; 17(2): 151-183.
- Кобалава Ж. Д., Мотовская Ю. В. Мониторирования артериального давления: методические аспекты и клиническое значение / Под ред. В. С. Моисеева. М.: Издат. группа "Сервье"; 1999.
- Суточное мониторирование артериального давления: (Метод. вопросы) / Рогоза А. Н., Никольский В. П., Ошепкова Е. В. и др. Под ред. Г. Г. Арабидзе, О. Ю. Атькова. М.: 1997.